JOHNSON & JOHNSON is 27.1x more valuable than Royalty Pharma plc by market capitalization ($573.98 B vs $21.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RPRX | JNJ |
|---|---|---|
| Market cap | $21.16 B | $573.98 B |
| US-listed rank | #600 | #20 |
| Revenue (latest FY) | $2.38B | $94.19B |
| Net income (latest FY) | $770.95M | $26.80B |
| Net margin | 32.4% | 28.5% |
| P/E (trailing FY) | 27.4 | 21.4 |
| SEC filings | 588 | 984 |
JOHNSON & JOHNSON is 27.1x more valuable than Royalty Pharma plc by market capitalization ($573.98 B vs $21.16 B).
In their latest fiscal years, Royalty Pharma plc reported $2.38B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Royalty Pharma plc and JOHNSON & JOHNSON, or browse the full rankings.